Developer docs
API playgroundTry for free, no card

Search company profiles

Fauna Bio

Full company profile

uuid00009zu

Namestring
Fauna Bio
Legal namestring
Fauna Bio
Websiteurl
faunabio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Fauna Bio is a private biotechnology company founded in 2018 and headquartered in Emeryville, California, that uses AI-driven comparative genomics to identify novel therapeutic targets for human diseases by studying genetic data from hibernating mammals and other extreme animal species. The company's core technology is the Convergence™ AI platform, built on an exclusive biobank of genetic data from more than 450 mammal species (including 13-lined ground squirrels, spiny mice, tenrecs, and elephant seals), a Centaur knowledge graph with 1 million nodes and 38 million edges, a 1-billion-parameter graph neural network, and an integrated multi-omic dataset spanning 46 billion sequence reads across transcriptomes, proteomes, and epigenomes. In June 2025, the company launched Fauna Brain™, an AI platform with autonomous agents that replicate drug-discovery workflows in minutes.

The company monetizes primarily through B2B pharmaceutical collaborations structured as multi-year licensing deals with upfront payments, equity investments, milestone payments, and royalties. Its flagship agreement is a December 2023 collaboration with Eli Lilly worth up to $494 million for obesity drug discovery, which achieved a target-designation milestone in March 2026. Fauna Bio also maintains a Novo Nordisk collaboration in obesity and fibrosis, NASA-funded space health programs (STASH, ADAPT, RADIANCE), and academic partnerships through the Zoonomia Consortium and universities including UW-Oshkosh, UNLV, UF, and Colorado State. Its proprietary pipeline is led by FAUN1083 for heart failure with preserved ejection fraction (HFpEF), which entered IND-enabling studies in Q4 2025 with first-in-human clinical entry targeted for 2026, supplemented by a retinal program (FAUN264G) and additional discovery-stage assets.

Short descriptiontext

Fauna Bio is a private biotech using AI-driven comparative genomics from hibernating mammals to identify novel therapeutic targets for human diseases. It licenses its Convergence platform to pharmaceutical partners and develops a proprietary pipeline led by FAUN1083 for heart failure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, comparative genomics therapeutics, hibernation biology research, pharmaceutical licensing deals, biomedical knowledge graphs
Industry1 code
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-driven drug discovery
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Licensing Deals
TypeLicensing Royalties
Description

Multi-year licensing agreements with pharmaceutical companies including upfront payments, equity investments, milestone payments tied to development and regulatory achievements, and royalties based on commercial sales. Example: $494M agreement with Eli Lilly including upfront, equity, and milestone components.

faunabio.com
2Collaborations and Research Partnerships
TypeProfessional Services
Description

Strategic collaborations with pharma companies for specific disease areas (obesity, fibrosis) using the company's AI platform, with payments for target designation and other milestone achievements.

finsmes.com
3Milestone Payments
TypeLicensing Royalties
Description

Payments triggered by specific achievements in drug discovery collaborations such as target designation, IND-enabling studies, clinical entry, and regulatory milestones.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Fauna Bio is an AI-driven drug discovery company that uses comparative genomics from 450+ mammal species—including hibernating animals like 13-lined ground squirrels, spiny mice, tenrecs, and elephant seals—to identify novel therapeutic targets for human diseases. Its core platform, Convergence™, combines a proprietary biobank, a billion-parameter Centaur knowledge graph, and AI components (Orca, Centaur, Leo) to discover drugs that mimic natural disease resistance mechanisms, validated through multi-year pharma collaborations (e.g., $494M Eli Lilly deal) and a proprietary pipeline led by FAUN1083 for HFpEF.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • FAUN1083 identified from just 60 samples from ground squirrels (vs 30,000+ needed in human studies)
+3 more records
Product overview1 text field

Fauna Bio is an AI-driven drug discovery company that leverages data from 100 million years of evolved disease resistance in mammals. The company's core offering consists of the Convergence™ AI platform and Fauna Brain™ AI system, which work together to identify novel therapeutic targets by studying how extreme animals like hibernating mammals resist and reverse disease. The platform analyzes genomic data from over 450 mammal species to discover drug targets, which are then validated using human genomics data. Fauna Bio's lead product is FAUN1083, a development candidate for Heart Failure with Preserved Ejection Fraction (HFpEF), currently in IND-enabling studies with clinical entry planned for 2026. The company also maintains a partnered obesity program with Eli Lilly worth up to $494M and additional pipeline programs in retinal disease and other indications. The company collaborates with the Zoonomia Consortium and academic partners to access genomic data from diverse mammal species.

Product and service1 record
1Convergence™ AI Platform
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

Multi-year strategic collaboration for obesity drug discovery using Fauna's Convergence AI platform. Deal includes upfront payment, equity investment, and eligibility for up to $494 million in milestone payments plus royalties. Target designation milestone achieved in March 2026.

2Zoonomia Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-01
Description

Collaboration producing whole-genome alignment of 240 mammals and protein-coding alignments for 428 mammals, featured in Science journal. Consortium includes 150+ researchers across 7 time zones.

faunabio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-01
Description

Collaboration on obesity and fibrosis-related diseases research using Fauna's comparative genomics approach and drug discovery platform.

4NASA
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple space-focused research programs including STASH, ADAPT, and RADIANCE studying hibernation mechanisms for astronaut health. Funded by NASA Innovative Advanced Concepts (NIAC) and Space Radiation Element.

faunabio.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Supporting Project RADIANCE for studying protective effects of hibernation against radiation, in collaboration with Italian Space Agency and NASA.

6Italian Space Agency (ASI)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Supporting Project RADIANCE for studying protective effects of hibernation against radiation exposure experienced during Mars missions.

faunabio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for hibernation research, including ASCRIPTS study at NASA-funded neutron irradiation facility exploring radioprotection in hibernating ground squirrels.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic collaboration to examine heart samples from tenrecs to study cardiac regeneration mechanisms.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic collaboration to use spiny mice to understand mechanisms of regeneration in brain and skin tissues.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Dedicated research space to work with 13-lined ground squirrel colony and perform in-vivo experiments.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company combining machine learning with biology to discover therapeutics. Operates a similar B2B model with pharma partnerships and an internal pipeline, competing directly with Fauna Bio in computational target identification and IND-stage programs.

TypeDirect peer
Description

AI-native biotech using high-throughput biology and machine learning to discover drugs across multiple therapeutic areas. Like Fauna Bio, it combines proprietary data generation with AI modeling and pursues pharma partnerships alongside an internal pipeline.

TypeDirect peer
Description

AI-driven precision medicine company focused on small-molecule drug discovery with multiple pharma collaborations. Comparable B2B partnership model and platform technology stack for accelerating preclinical candidate identification.

TypeDirect peer
Description

Computational chemistry and AI-based molecular simulation platform for drug discovery, serving pharma clients with software and collaborative programs. Direct competitor in the AI-driven drug design space with both platform and partnered pipeline economics.

TypeDirect peer
Description

AI-drug-discovery company using knowledge graphs and machine learning to identify novel therapeutic targets across diseases. Closely comparable in using large biomedical knowledge graphs and target-discovery workflows with pharma partnerships.

TypeEmerging player
Description

AI-native biotech using graph neural networks and physics-based methods to accelerate small-molecule drug discovery. Emerging peer with overlapping AI infrastructure and target-to-lead workflow, but focused on chemistry rather than animal-derived biology.

7Isomorphic Labs
TypeDirect peer
Description

Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction and AI to pharmaceutical R&D. Competes for the same pharma partnership dollars with an AI-first platform approach to target identification and molecular design.

TypeBroad incumbent
Description

Large-scale synthetic biology and biosecurity platform with cell engineering and organism design capabilities. Broad incumbent with an AI-driven biology platform that touches drug discovery, though it is more diversified into industrial biotech than Fauna Bio's pure therapeutic focus.

9Zymergen (Ginkgo)
TypeEmerging player
Description

AI-driven bioengineering company focused on genomics and synthetic biology for industrial applications. Adjacent peer in the AI-meets-biology platform category, though less directly focused on human therapeutics.

TypeEmerging player
Description

AI-enabled antibody discovery platform using high-throughput screening and computational methods to identify therapeutic antibodies. Adjacent platform biotech combining proprietary data and AI with pharma partnerships, with more focus on antibody modalities than Fauna Bio's small-molecule and target approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fauna Bio

AI-driven drug discoveryfaunabio.com

Fauna Bio is a private biotech using AI-driven comparative genomics from hibernating mammals to identify novel therapeutic targets for human diseases. It licenses its Convergence platform to pharmaceutical partners and develops a proprietary pipeline led by FAUN1083 for heart failure.

What Fauna Bio does

Fauna Bio is a private biotechnology company founded in 2018 and headquartered in Emeryville, California, that uses AI-driven comparative genomics to identify novel therapeutic targets for human diseases by studying genetic data from hibernating mammals and other extreme animal species. The company's core technology is the Convergence™ AI platform, built on an exclusive biobank of genetic data from more than 450 mammal species (including 13-lined ground squirrels, spiny mice, tenrecs, and elephant seals), a Centaur knowledge graph with 1 million nodes and 38 million edges, a 1-billion-parameter graph neural network, and an integrated multi-omic dataset spanning 46 billion sequence reads across transcriptomes, proteomes, and epigenomes. In June 2025, the company launched Fauna Brain™, an AI platform with autonomous agents that replicate drug-discovery workflows in minutes.

The company monetizes primarily through B2B pharmaceutical collaborations structured as multi-year licensing deals with upfront payments, equity investments, milestone payments, and royalties. Its flagship agreement is a December 2023 collaboration with Eli Lilly worth up to $494 million for obesity drug discovery, which achieved a target-designation milestone in March 2026. Fauna Bio also maintains a Novo Nordisk collaboration in obesity and fibrosis, NASA-funded space health programs (STASH, ADAPT, RADIANCE), and academic partnerships through the Zoonomia Consortium and universities including UW-Oshkosh, UNLV, UF, and Colorado State. Its proprietary pipeline is led by FAUN1083 for heart failure with preserved ejection fraction (HFpEF), which entered IND-enabling studies in Q4 2025 with first-in-human clinical entry targeted for 2026, supplemented by a retinal program (FAUN264G) and additional discovery-stage assets.

Fauna Bio firmographics

Firmographics
Name
Fauna Bio
Legal name
Fauna Bio
Website
https://faunabio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Fauna Bio is a private biotech using AI-driven comparative genomics from hibernating mammals to identify novel therapeutic targets for human diseases. It licenses its Convergence platform to pharmaceutical partners and develops a proprietary pipeline led by FAUN1083 for heart failure.
Ownership category
akta.pro rank

Fauna Bio industry classification

Industry
Product category
AI-driven drug discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Comparative genomics therapeutics
  • Hibernation biology research
  • Pharmaceutical licensing deals
  • Biomedical knowledge graphs

Where Fauna Bio is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Fauna Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Licensing Deals: Multi-year licensing agreements with pharmaceutical companies including upfront payments, equity investments, milestone payments tied to development and regulatory achievements, and royalties based on commercial sales. Example: $494M agreement with Eli Lilly including upfront, equity, and milestone components.
  2. Collaborations and Research Partnerships: Strategic collaborations with pharma companies for specific disease areas (obesity, fibrosis) using the company's AI platform, with payments for target designation and other milestone achievements.
  3. Milestone Payments: Payments triggered by specific achievements in drug discovery collaborations such as target designation, IND-enabling studies, clinical entry, and regulatory milestones.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Fauna Bio product offering

Product offering

Core offering

Fauna Bio is an AI-driven drug discovery company that uses comparative genomics from 450+ mammal species—including hibernating animals like 13-lined ground squirrels, spiny mice, tenrecs, and elephant seals—to identify novel therapeutic targets for human diseases. Its core platform, Convergence™, combines a proprietary biobank, a billion-parameter Centaur knowledge graph, and AI components (Orca, Centaur, Leo) to discover drugs that mimic natural disease resistance mechanisms, validated through multi-year pharma collaborations (e.g., $494M Eli Lilly deal) and a proprietary pipeline led by FAUN1083 for HFpEF.

Product overview

Fauna Bio is an AI-driven drug discovery company that leverages data from 100 million years of evolved disease resistance in mammals. The company's core offering consists of the Convergence™ AI platform and Fauna Brain™ AI system, which work together to identify novel therapeutic targets by studying how extreme animals like hibernating mammals resist and reverse disease. The platform analyzes genomic data from over 450 mammal species to discover drug targets, which are then validated using human genomics data. Fauna Bio's lead product is FAUN1083, a development candidate for Heart Failure with Preserved Ejection Fraction (HFpEF), currently in IND-enabling studies with clinical entry planned for 2026. The company also maintains a partnered obesity program with Eli Lilly worth up to $494M and additional pipeline programs in retinal disease and other indications. The company collaborates with the Zoonomia Consortium and academic partners to access genomic data from diverse mammal species.

Differentiator

Problem solved

Functional benefit

Products and services

  • Convergence™ AI Platform

Quantifiable outcome

  • FAUN1083 identified from just 60 samples from ground squirrels (vs 30,000+ needed in human studies)
  • +3 more outcomes

Companies that use Fauna Bio

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Fauna Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Fauna Bio partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship, core and supporting.

  • Eli LillyflagshipStrategic or Co-development Partner · 1 December 2023Multi-year strategic collaboration for obesity drug discovery using Fauna's Convergence AI platform. Deal includes upfront payment, equity investment, and eligibility for up to $494 million in milestone payments plus royalties. Target designation milestone achieved in March 2026.
  • Zoonomia ConsortiumcoreStrategic or Co-development Partner · 1 April 2023Collaboration producing whole-genome alignment of 240 mammals and protein-coding alignments for 428 mammals, featured in Science journal. Consortium includes 150+ researchers across 7 time zones.
  • Novo NordiskcoreStrategic or Co-development Partner · 1 September 2021Collaboration on obesity and fibrosis-related diseases research using Fauna's comparative genomics approach and drug discovery platform.
  • NASAcoreStrategic or Co-development PartnerMultiple space-focused research programs including STASH, ADAPT, and RADIANCE studying hibernation mechanisms for astronaut health. Funded by NASA Innovative Advanced Concepts (NIAC) and Space Radiation Element.
  • Canadian Space Agency (CSA)supportingStrategic or Co-development PartnerSupporting Project RADIANCE for studying protective effects of hibernation against radiation, in collaboration with Italian Space Agency and NASA.
  • Italian Space Agency (ASI)supportingStrategic or Co-development PartnerSupporting Project RADIANCE for studying protective effects of hibernation against radiation exposure experienced during Mars missions.
  • Colorado State UniversitycoreStrategic or Co-development PartnerAcademic partnership for hibernation research, including ASCRIPTS study at NASA-funded neutron irradiation facility exploring radioprotection in hibernating ground squirrels.
  • University of Nevada, Las Vegas (UNLV)supportingStrategic or Co-development PartnerAcademic collaboration to examine heart samples from tenrecs to study cardiac regeneration mechanisms.
  • University of Florida (UF)supportingStrategic or Co-development PartnerAcademic collaboration to use spiny mice to understand mechanisms of regeneration in brain and skin tissues.
  • University of Wisconsin-OshkoshsupportingStrategic or Co-development PartnerDedicated research space to work with 13-lined ground squirrel colony and perform in-vivo experiments.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Fauna Bio competitors and assessment

Company assessment

Direct peers

  • Insitro: AI-driven drug discovery company combining machine learning with biology to discover therapeutics. Operates a similar B2B model with pharma partnerships and an internal pipeline, competing directly with Fauna Bio in computational target identification and IND-stage programs.
  • Recursion Pharmaceuticals: AI-native biotech using high-throughput biology and machine learning to discover drugs across multiple therapeutic areas. Like Fauna Bio, it combines proprietary data generation with AI modeling and pursues pharma partnerships alongside an internal pipeline.
  • Exscientia: AI-driven precision medicine company focused on small-molecule drug discovery with multiple pharma collaborations. Comparable B2B partnership model and platform technology stack for accelerating preclinical candidate identification.
  • Schrödinger: Computational chemistry and AI-based molecular simulation platform for drug discovery, serving pharma clients with software and collaborative programs. Direct competitor in the AI-driven drug design space with both platform and partnered pipeline economics.
  • BenevolentAI: AI-drug-discovery company using knowledge graphs and machine learning to identify novel therapeutic targets across diseases. Closely comparable in using large biomedical knowledge graphs and target-discovery workflows with pharma partnerships.
  • Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction and AI to pharmaceutical R&D. Competes for the same pharma partnership dollars with an AI-first platform approach to target identification and molecular design.

Emerging players

  • Genesis Therapeutics: AI-native biotech using graph neural networks and physics-based methods to accelerate small-molecule drug discovery. Emerging peer with overlapping AI infrastructure and target-to-lead workflow, but focused on chemistry rather than animal-derived biology.
  • Zymergen (Ginkgo): AI-driven bioengineering company focused on genomics and synthetic biology for industrial applications. Adjacent peer in the AI-meets-biology platform category, though less directly focused on human therapeutics.
  • AbCellera: AI-enabled antibody discovery platform using high-throughput screening and computational methods to identify therapeutic antibodies. Adjacent platform biotech combining proprietary data and AI with pharma partnerships, with more focus on antibody modalities than Fauna Bio's small-molecule and target approach.

Broad incumbents

  • Ginkgo Bioworks: Large-scale synthetic biology and biosecurity platform with cell engineering and organism design capabilities. Broad incumbent with an AI-driven biology platform that touches drug discovery, though it is more diversified into industrial biotech than Fauna Bio's pure therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Fauna Bio social profiles

Digital presence

Fauna Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fauna Bio leadership team

Management profile

Number of profiles

Profiles4 records

Fauna Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fauna Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fauna Bio

What does Fauna Bio do?

Fauna Bio is an AI-driven drug discovery company that uses comparative genomics from 450+ mammal species—including hibernating animals like 13-lined ground squirrels, spiny mice, tenrecs, and elephant seals—to identify novel therapeutic targets for human diseases. Its core platform, Convergence™, combines a proprietary biobank, a billion-parameter Centaur knowledge graph, and AI components (Orca, Centaur, Leo) to discover drugs that mimic natural disease resistance mechanisms, validated through multi-year pharma collaborations (e.g., $494M Eli Lilly deal) and a proprietary pipeline led by FAUN1083 for HFpEF.

Is Fauna Bio a public or private company?

Fauna Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Fauna Bio founded?

Fauna Bio was founded in 2018. It employs 11 to 50 people.

Where is Fauna Bio based?

Fauna Bio is headquartered in Berkeley, United States, in the North America region.

How does Fauna Bio make money?

Three revenue lines are on record. Pharmaceutical Licensing Deals are the primary driver. The others are collaborations and Research Partnerships and milestone Payments.

Who are Fauna Bio's main competitors?

Direct peers on record are Insitro, Recursion Pharmaceuticals, Exscientia, Schrödinger, BenevolentAI and Isomorphic Labs. Emerging players are Genesis Therapeutics, Zymergen (Ginkgo) and AbCellera. Ginkgo Bioworks is listed as a broad incumbent.

Does Fauna Bio have an API?

No public API is recorded for Fauna Bio.

What industry is Fauna Bio in?

Fauna Bio's product category is AI-driven drug discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyFauna Bio designates second obesity target with LillyFauna Bio announced a second obesity target from a different tissue under its collaboration with Eli Lilly. The designation triggers additional payments under the multi-year discovery collaboration.Longevity.TechnologyHibernator biology yields a second obesity targetFauna Bio announced on 11 November a second obesity target derived from hibernator biology, building on its collaboration with Eli Lilly. The company's AI platform, based on mammal genomes, identified the target from hibernating animals' ability to swing body weight and metabolism.Business Wire BlogFauna Bio Announces Second Target Designation in Obesity Discovery Collaboration with LillyFauna Bio announced a second target designation in its obesity discovery collaboration with Eli Lilly, advancing a target identified via its Convergence AI platform. The milestone triggers additional payments under the agreement, though details were not disclosed. The collaboration, signed in December 2023, includes up to $494 million in milestone payments and royalties.Longevity.TechnologyWhat animals can teach us about reversing age-related diseaseA new episode of the Longevity Technology Unlocked podcast features Daniel Oliver of Rejuvenate Bio and Ashley Zehnder of Fauna Bio discussing how studying animals can accelerate human longevity breakthroughs. Rejuvenate Bio is developing gene therapies in companion animals, particularly dogs, to treat age-linked disease while building infrastructure for human programs, using veterinary commercialization revenues to fund human development. Fauna Bio studies hibernating species like ground squirrels that endure extreme physiological stress and recover routinely, using these natural repair mechanisms to identify drug targets that human datasets may never reveal. Both founders argue that aging and age-related decline may be more reversible than currently assumed, with single therapeutic combinations showing promise across multiple conditions including heart failure, kidney failure, and metabolic dysfunction in animal models.The Pharma LetterLilly-partnered Fauna announces designation of novel obesity targetFauna Bio, a comparative genomics specialist, designated a novel obesity target under its collaboration with Eli Lilly, signed in December 2023. The target was identified using Fauna's Convergence AI platform and represents a potential first-in-class approach to treating obesity by leveraging insights from hibernating mammals.Business Wire BlogFauna Bio Announces Target Designation Milestone in Obesity Discovery CollaborationFauna Bio announced the designation of a novel obesity target under its strategic discovery collaboration with Eli Lilly, initiated in December 2023, triggering a payment to Fauna Bio. The target was identified using Fauna Bio's Convergence™ AI platform, which analyzes genomic data from over 450 mammal species to leverage metabolic insights from hibernating animals for treating obesity. This milestone validates Fauna Bio's comparative genomics approach and advances the collaboration into its next phase.FierceBiotechLilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammalsFauna Bio, a California biotech, has identified a drug target for obesity treatment by analyzing genomic data from over 450 mammal species, including 60 hibernators, using its Convergence AI platform. The discovery triggers a milestone payment under Fauna's 2023 partnership with Eli Lilly, which includes up to $494 million in potential biobucks. The target represents a first-in-class approach to treating obesity by leveraging insights from how hibernating mammals naturally regulate body weight and metabolism.Longevity.TechnologyFauna Bio hits key milestone in Lilly obesity drug collabCalifornia-based longevity biotech Fauna Bio has designated a metabolic disease drug target in its obesity research partnership with Eli Lilly, triggering an undisclosed milestone payment under a 2023 agreement potentially worth up to $494 million. The target was identified using the company's AI discovery platform, which analyzes biological data from hibernating mammals like ground squirrels to uncover metabolic regulation mechanisms. Lilly will now be responsible for optimizing and advancing the therapeutic candidate through development, as the collaboration seeks to address obesity through novel pathways beyond current GLP-1 treatments.BioSpaceFauna Bio Announces Target Designation Milestone in Obesity Discovery CollaborationFauna Bio announced a target designation milestone under its strategic obesity discovery collaboration with Eli Lilly, initiated in December 2023, with the target identified using Fauna Bio's Convergence™ AI platform leveraging insights from hibernating mammals. The milestone triggers a payment to Fauna Bio under the collaboration agreement. The achievement represents a potential first-in-class approach to treating obesity and validates Fauna Bio's comparative genomics platform, which analyzes genomic data from over 450 mammal species.The ScientistAging Research Takes the Spotlight During JPM Week at the 2026 Biotech ShowcaseFour aging-focused biotech companies—Gero, Fauna Bio, Cellino, and R3 Biotechnologies—participated in a panel at the 2026 Biotech Showcase during JP Morgan Healthcare Conference week in San Francisco, each presenting distinct approaches to longevity and healthspan therapeutics. Gero announced a collaboration with Chugai to develop antibody drugs for age-related targets using AI analysis of over 100 million electronic health records, while Fauna Bio identified therapeutic targets for heart failure by studying hibernating ground squirrels. Cellino is developing an AI-based manufacturing platform for personalized iPSC cell therapies in partnership with Mass General Brigham, and R3 Biotechnologies is working on growing organ systems to replace animal drug testing models. The panel noted that ARPA-H is the most active funder of aging research in the U.S., with China and Japan identified as competitive in the autologous iPSC space.